Part 2/2 - In this episode we are joined by fan favourite Nick Gastevich aka CannaVestments to do a deep dive into 7 of our favourite up and coming mid and small cap MSOs. Part 2 has smaller cap companies with potentially more upside but also additional execution risk.

In part 2 of this analysis we go over:

Our Picks for #4-7:

4) Pharmacann (private)

5) Vireo / Goodness Growth

6) Jushi

7) Cansortium

- Ranking: Why we feel this way

- Origins: Genesis of each company and the progress that has been made

- Value: Current valuation and where we see future upside potential

- Capital Structure: Shares outstanding, debt and cash on hand

- Footprint: Core states today and future growth states

- M&A: Past and future prospects

- Risks and Challenges with each company

Thanks to Nick for joining us for this epic 2 part series

Connect with Nick:

Twitter - https://twitter.com/CannaVestments

LinkedIn - https://www.linkedin.com/in/nicholas-gastevich-75841346/

Family Office Website - https://www.vginvests.com/ 

In this episode we are joined by fan favourite Nick Gastevich aka CannaVestments to do a deep dive into 7 of our favourite up and coming mid and small cap MSOs. We also go over market sentiment, reactions to Schumers bill and why it is worthwhile to look at mid cap MSOs.

In part 1 of this analysis we go over:

Our Top 3 Picks:

1) AYR Wellness

2) Ascend Wellness

3) Columbia Care

- Ranking: Why we feel this way

- Origins: Genesis of each company and the progress that has been made

- Value: Current valuation and where we see future upside potential

- Capital Structure: Shares outstanding, debt and cash on hand

- Footprint: Core states today and future growth states

- M&A: Past and future prospects

- Risks and Challenges with each company

Coming next week - part 2 of our analysis where we review picks #4-7

Connect with Nick:

Twitter - https://twitter.com/CannaVestments

LinkedIn - https://www.linkedin.com/in/nicholas-gastevich-75841346/

Family Office Website - https://www.vginvests.com/ 

In this episode we are once again joined with a special guest, Chris Murray.  Chris and Abi discuss a wide array of topics that affect the social stigma in cannabis along with potential factors which are affecting other sectors and could spill over to cannabis.

First we briefly touch on Sha'carri Richardson's recent disqualification in the upcoming Tokyo Olympics after testing positive for THC.

Followed by a look into ESG, Environmental, Social and Governance, which refers to the three key factors when measuring the sustainability and ethical impact of a company.  ESG is affecting many other industries including meat, agriculture, metals refining, crypto mining and others.  We discuss if this is something cannabis investors should be concerned about.

Lastly, we look back on Tilray and discuss how a restricted cap combined with retail demand on a large US exchange created a perfect storm for the price to shoot to the moon.

As always, we hope you enjoyed this episode.

In this episode we discuss last week's Jefferies ~300 page research report on the US Cannabis industry. The investment bank covers many MSOs, US markets and projects out sales to 2030. 

We discuss why we think the headline is true but potentially misleading, try to measure how much upside we see in the next 2-3 years, discuss forward margins and EBITDA multiples and discuss our strategy for earning outsized returns to build our portfolio.

Nostalgia time! In this episode we dive into our experiences over the last 2+ years and discuss how the market has evolved since we started this podcast. While many things have changed, the parallels between market boom and bust, the nature of retail investors and the emotional turmoil of the highs and lows are eerily similar to 2019. We discuss how our past experiences (and mistakes) have hopefully made us better cannabis investors in 2021.

A special thank you to all the listeners who have been with us through the ups and downs; 100 episodes down and we are just getting started!

In this mega-episode our good friend Nick Gastevich joins us for the Q1 quarterly review of Curaleaf, Trulieve, Cresco Labs, Green Thumb and Verano.

We do a deep dive into profitability, core footprints, valuation and how we see the future for each company. 

As the broader peer set trades between 10-14X '22 EBITDA we feel the time is right for acquiring these big 5 MSOs. We discuss the theme of value hidden in plain sight for these "Green Chip" companies.

Thanks to Nick for another great and extensive review

Connect with Nick:

Twitter - https://twitter.com/CannaVestments

LinkedIn - https://www.linkedin.com/in/nicholas-gastevich-75841346/

Family Office Website - https://www.vginvests.com/ 

We are joined by a special guest, Andrew Semple from Echelon Wealth Partners.  Andrew was recently highlighted as the top performing analyst on Bay St by the Globe and Mail.  He's a fundamental investor at heart and finds value in growth stocks.

In this episode we gain insights on federal reform, select limited license states and US MSO's.  As well we gain insights on how Semple begins an analysis on a specific market.

Companies mentioned: AYR Wellness, Columbia Care, Curaleaf, GTI, Jushi, Trulieve, Verano.

Links to Andrew’s Research:

·  Click here for Andrew’s Weekly Summary June 11, 2021

Link to Andrew's analyst disclaimer - https://drive.google.com/file/d/1Qc3gGCQQjDVuxi3xKE_qF6wxVEP-_HBM/view?usp=sharing 

Correction - Chris mentions Hexo/Truss drinks in the US containing THC. This is an error - these drinks are CBD only.

We are joined by a special guest, Chris Murray.  Chris is a veteran in the cannabis sector.  He was employee number 7 at Canopy Growth, which was the first Canadian LP to go public on the TSX and NASDAQ and was dubbed the first unicorn in the cannabis sector.   Canopy played a pivotal role in shaping today's cannabis sector and today we are joined by Chris who had first hand experience in catching the monumental growth riding the unicorn wave.

In this episode we gain insights on what happened at Canopy.  We take a deeper dive into the importance of company culture and how strategic decisions affect it.  We look at the differences in strategies between a medical focused company vs an adult use cannabis company and why it's important to differentiate between the two types of customers.  As M&A continues to accelerate in the sector, in this episode you'll learn how to view M&A opportunities through a unique qualitative lense.

Companies mentioned: Canopy, Aphria, Aurora, HEXO & Trulieve.

In this episode we dive deep into the state of the cannabis retail market in Florida. Florida has long been one of our favourite markets. Today's guest was on the forefront of the Florida market from a different side of the table. As a real estate developer focused on Florida retail, cannabis operators came onto Randy's radar. He helped these companies rapidly grow their retail footprint over the last few years by being able to source appropriately zoned properties and deal with the variety of issues that complicate the life of dispensaries. But Randy soon realized the payoff for accomplishing these deals could be enormous.

In this episode:

- How Randy stumbled into the industry

- The early days of Florida's medical market

- Doing GTI Florida's first deal

- What the heydey of opening dispensaries was like

- His thoughts on who's doing it well and how good Trulieve really is

- The secrets to success at this stage of the industry

Thanks to Randy for joining for a very fun and informative chat!

Audio Note: There was an echo in this episode we mostly fixed. However the audio may at times be a little odd. Thanks for understanding

In this episode we are joined by the leading cannabis analyst Alan Brochstein. Alan is known for being the sheriff of the wild west of cannabis and applying his deep analytical insights in the cannabis industry. 

He is founder of New Cannabis Ventures and shares his insights as "the maven" of 420investor. Alan regularly helps us form our opinions on the cannabis space and helps investors make better investment decisions. 

He joins us today in a broad ranging discussion about investor psychology, cannabis fundamentals, company specific discussions and much more. Thanks to Alan for joining us as always.

Twitter - https://twitter.com/Invest420